

PART V

Neuroscience

Chapters 11–12

The Brain on Meth

How a drug that floods the brain with dopamine reshapes the very circuits of reward, learning, memory, and self-control — and why those changes make the behavior so hard to stop.

Chapter 8 described, at the level of molecules and transporters, how methamphetamine elevates synaptic monoamines. This chapter follows that surge upward into the circuits it perturbs. The central paradox of stimulant neuroscience is that the same dopamine signal that makes the drug intensely rewarding in the short term progressively degrades, with repeated use, the brain systems responsible for reward, judgment, and control — so that the drug comes to feel necessary even as it delivers less and less.

Reward circuitry

The brain's reward system is organized around dopamine projections from the ventral tegmental area to the nucleus accumbens and connected limbic and cortical regions. Natural rewards — food, social connection, novelty — produce modest, regulated dopamine signals in this circuit that reinforce adaptive behavior. Methamphetamine produces a dopamine signal of a magnitude no natural reward approaches, and it does so by the direct pharmacological mechanism of Chapter 8 rather than through the normal route of earned reward. Repeated exposure to this supraphysiological signal drives the system to adapt in the direction of *down-regulation*: dopamine D2-type receptor availability falls, and the circuit settles into a relatively hypodopaminergic state in which ordinary rewards feel muted and the drug becomes the most reliable source of dopaminergic stimulation.^{5,6} This blunting of the reward system is not a metaphor but a measurable change, and it is one of the neural foundations of addiction described in Part VIII.

Neuroplasticity

Beneath these circuit-level shifts lies neuroplasticity — the capacity of synapses to strengthen, weaken, and remodel. Methamphetamine drives lasting changes in synaptic strength (long-term potentiation and depression) and in the physical architecture of neurons, including alterations in dendritic branching and spine density, particularly within the glutamatergic projections linking the prefrontal cortex to the striatum. These changes are sometimes summarized as "addiction memory": the drug recruits the brain's normal machinery for learning and consolidates a powerful, durable association between drug cues, drug taking, and reward. Because this remodeling co-opts the same mechanisms that underlie ordinary learning, it is deeply entrenched and slow to reverse, which helps explain the persistence of relapse risk long after drug use stops.

Learning

The learning that methamphetamine drives is largely associative and, in the language of addiction neuroscience, a matter of *incentive salience* — the process by which drug-associated cues acquire disproportionate motivational pull. Places, people, paraphernalia, and internal states that have been paired with drug use become potent triggers that can provoke craving automatically, often outside conscious awareness. This conditioned learning is one reason environmental context matters so much to relapse and recovery (Parts VIII and XI): the cues themselves have been wired into the motivational system.

Memory

Beyond drug-cue learning, methamphetamine affects the brain's general memory systems, with the hippocampus and prefrontal cortex among the regions implicated. Chronic use is associated with measurable impairments in verbal learning and memory and in visual memory, and animal evidence indicates that the drug can reduce synaptic transmission in the dorsal hippocampus and alter the plasticity that normally supports learning and recall.^{1,8} The result, at the level of everyday function, is that memory difficulties are a common and well-documented feature of methamphetamine use disorder, not an incidental complaint.

Executive function

Perhaps the most consequential cognitive territory is executive function — the prefrontal-cortex-dependent capacities for inhibitory control, working memory, planning, and decision-making that allow a person to override impulses in the service of longer-term goals. Methamphetamine use is associated with deficits across precisely these domains, and the same orbitofrontal and prefrontal regions whose metabolism tracks with reduced D2 receptor availability are central to self-regulation.^{6,8} The clinical importance of this is direct: weakened top-down control, layered on top of a sensitized motivational pull toward the drug and a blunted response to other rewards, produces the characteristic pattern of compulsive use against a person's own stated intentions. Executive dysfunction also predicts worse treatment outcomes — higher dropout and relapse — which is why it has become a target for the rehabilitation approaches discussed in the next chapter.⁹

Long-Term Brain Changes

The evidence for lasting neurotoxic injury — and, equally important, the evidence that the brain can recover at least partially when use stops.

This chapter addresses one of the most consequential and most misunderstood questions about methamphetamine: how much lasting harm does it do to the brain, and is that harm permanent? The honest answer has two parts that must be held together. The evidence for genuine neurotoxic injury is substantial and should not be minimized; and the evidence that some of that injury partially reverses with sustained abstinence is also real and should not be ignored. Neither the alarmist claim of total, irreversible destruction nor the dismissive claim that the brain is unharmed survives the data.

Neurotoxicity evidence

In both animal models and human studies, methamphetamine exposure is associated with long-term damage to dopaminergic and serotonergic axon terminals, particularly in the striatum, hippocampus, and prefrontal cortex.¹ The neurochemical signature of this injury is consistent across studies: reductions in tyrosine hydroxylase and tryptophan hydroxylase (the rate-limiting enzymes for dopamine and serotonin synthesis), decreases in tissue dopamine and serotonin content, reduced expression of the dopamine and serotonin transporters (DAT and SERT), and decreased dopamine D2 receptor density.¹ Notably, this dopaminergic terminal damage generally does not produce the classic motor features of Parkinson's disease, even though it affects overlapping systems.¹

The mechanisms, foreshadowed in Chapter 8, converge on a small set of interacting processes. Excess cytoplasmic and extracellular dopamine auto-oxidizes to form dopamine quinone and reactive oxygen and nitrogen species, generating **oxidative stress** that damages terminals and impairs mitochondria.² The drug drives **excitotoxicity** by increasing glutamate release while reducing its clearance by astrocytes, overactivating NMDA receptors and admitting damaging calcium influx.³ It provokes **neuroinflammation**, activating microglia and astrocytes (reactive

gliosis) with release of pro-inflammatory cytokines such as TNF- α , IL-1 β , and IL-6.⁴ And **hyperthermia** — the elevated body temperature that frequently accompanies use, worsened by hot or crowded environments — amplifies all of these processes, accelerating dopamine oxidation and oxidative injury.² Together these pathways drive an oxidative-stress-mediated cascade of mitochondrial and endoplasmic-reticulum stress, apoptosis, and blood–brain-barrier disruption.

Mechanism	Core process
Oxidative stress	Dopamine autooxidation → dopamine quinone + ROS/RNS; mitochondrial dysfunction
Excitotoxicity	↑ glutamate, ↓ astrocytic uptake → NMDAR overactivation → Ca ²⁺ influx
Neuroinflammation	Microglial/astrocyte activation; TNF- α , IL-1 β , IL-6; reactive gliosis
Hyperthermia	Amplifies dopamine oxidation and oxidative injury at the terminal

Imaging studies

Human neuroimaging has been central to establishing these findings in living people. Positron emission tomography (PET) studies have documented reduced striatal dopamine transporter availability, low dopamine D2-type receptor availability, and depressed regional brain glucose metabolism in people who use methamphetamine, with the landmark work of Volkow and colleagues showing that low D2 receptor availability is associated with reduced metabolism in the orbitofrontal cortex — linking a neurochemical deficit to the executive regions discussed in Chapter 11.^{5,6} Structural MRI studies add evidence of gray-matter volume deficits and white-matter changes, particularly in frontal and limbic regions, that accompany the executive and memory difficulties seen clinically.⁸ Importantly, the degree of dopamine transporter loss has been shown to correlate with the severity of neuropsychological impairment, tying the imaging findings directly to function.⁵

Recovery

The recovery evidence is where careful framing matters most. The most-cited demonstration comes again from Volkow and colleagues, who found that striatal dopamine transporter availability was roughly 20 percent greater in people abstinent for 12 to 17 months than in those abstinent for only about 6 months — direct evidence that this marker of dopaminergic function recovers, at least partially, with protracted abstinence.⁵ Brain glucose metabolism, depressed shortly after cessation, also shows partial recovery in some regions (notably the thalamus) over time.⁷ Three caveats keep this from being a simple story of reversal. First, recovery is *partial*, not complete. Second, the rate and extent vary widely between individuals. Third, recovery of the dopamine transporter has not reliably translated into full restoration of cognitive performance — some neuropsychological deficits persist well after transporter markers improve — and recovery of D2-type receptors with abstinence is, as yet, not clearly established.⁷ The accurate summary is therefore one of meaningful but incomplete recovery: the brain is not frozen in its damaged state, but neither does abstinence simply return it to baseline.

Cognitive rehabilitation

Because cognitive deficits both impair daily functioning and predict worse treatment outcomes, supporting cognitive recovery has become an active area of intervention, though the evidence base is still developing and the interventions are best understood as adjuncts to, not replacements for, established addiction treatment. A meta-analysis spanning dozens of studies confirms that methamphetamine use disorder is associated with deficits across attention, executive function, verbal fluency, verbal learning and memory, visual memory, and working memory — defining the targets for remediation.⁸ **Cognitive remediation** approaches, which train executive skills through strategy learning, have shown promise; in a meta-analysis of cognitive-boosting interventions for addiction, Goal Management Training emerged as among the most promising.⁹ **Aerobic exercise** has attracted particular interest as a low-risk adjunct: controlled studies report improvements in working memory and inhibitory control and reductions in craving

among people in treatment for methamphetamine use disorder, and animal models suggest a plausible mechanism, with treadmill exercise up-regulating striatal D2 receptors and supporting dopaminergic recovery.¹⁰ Finally, abstinence itself, sustained over months, remains the foundation on which these gains are built. The realistic message for clinicians and for people in recovery is one of grounded hope: cognitive function is not fixed, and time, structured rehabilitation, and physical activity can each contribute to its improvement.

References — Part V

Listed in order of first citation within Part V. Numbering restarts each installment; the apparatus is to be consolidated on final assembly. Sources current as of 2026.

1. Reviews of methamphetamine neurotoxicity documenting long-term dopaminergic and serotonergic terminal damage in striatum, hippocampus, and prefrontal cortex, with reductions in tyrosine/tryptophan hydroxylase, DA/5-HT content, DAT/SERT, and D2 receptors. (Krasnova IN, Cadet JL; "Recent Advances in Methamphetamine Neurotoxicity Mechanisms," PMC4377385; "Neurotoxicity of methamphetamine: main effects and mechanisms," PMC8338805.)
2. Oxidative-stress mechanism: dopamine autooxidation to dopamine quinone and reactive oxygen/nitrogen species; mitochondrial dysfunction; hyperthermia as an amplifier of dopamine oxidation. (TBHQ neurotoxicity review, PMC7735854; "Methamphetamine-Induced Neuronal Damage," PMC7457172.)
3. Excitotoxicity: methamphetamine increases glutamate release and reduces astrocytic uptake, overactivating NMDA receptors with calcium influx. (PMC8338805; "Neurotoxicity mechanisms... of six common recreational drugs," *Frontiers in Pharmacology*, 2025, 1526270.)
4. Neuroinflammation: microglial and astrocyte activation (reactive gliosis) with TNF- α , IL-1 β , IL-6, and NF- κ B signaling. ("The Main Molecular Mechanisms Underlying Methamphetamine-Induced Neurotoxicity," *Front. Mol. Neurosci.* 2018, PMC5994595; Sekine et al.)
5. Volkow ND, Chang L, Wang G-J, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. *J Neurosci.* 2001;21(23):9414–9418. (Striatal DAT ~20% greater at 12–17 months vs. 6 months abstinence; DAT correlated with neuropsychological performance.)
6. Volkow ND, Chang L, Wang G-J, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. *Am J Psychiatry.* 2001;158(12):2015–2021.
7. Evidence on variable and incomplete recovery: persistent deficits after cessation (McCann et al., 2008); partial recovery of brain glucose metabolism, notably thalamic (Wang et al.); D2/D3 receptor recovery with abstinence not clearly established (Robertson CL, et al., PMC4832026).
8. Potvin S, et al. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis (44 studies; 1,592 MA-dependent vs. 1,820 controls) — deficits in attention, executive function, verbal fluency, verbal learning/memory, visual memory, and working memory; structural MRI gray/white-matter findings. (ScienceDirect S030646031830025X; multimodal MRI studies of early abstinence.)
9. Cognitive remediation for executive dysfunction in methamphetamine use disorder, including Goal Management Training; Anderson AC, et al. Cognitive-boosting interventions for impulsivity in addiction: systematic review and meta-analysis. *Addiction.* 2021;116:3304–3319. (*Frontiers in Psychiatry*, 2022, 876018.)

10. Aerobic exercise as adjunct: controlled studies showing improved working memory/inhibitory control and reduced craving in methamphetamine use disorder; animal evidence that treadmill exercise up-regulates striatal D2 receptors. (Exercise–neuroplasticity reviews, PMC12730288 / MDPI Brain Sci. 2025; PMC11140390; exercise–D2/D3 imaging trial, PMC4832026.)

End of Part V — Neuroscience (Chapters 11–12)

*Part VI — Medicine (Chapters 13–15: Legitimate Medical Uses; Side Effects; Over-dose)
continues the volume.*